Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity

    NEXT STORY
    Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
    PREV STORY
    Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BioFit: Real Side Effects Risks or Legit Weight Loss Results (April 2021 Review)

    author_avatar
    NASDAQ Market News

    Nabriva Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

    - Company preparing for potential commercialization of two first-in-class antibiotics, Lefamulin (IV and Oral) ...

    author_avatar
    NASDAQ Market News

    Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Actions Against Sorrento Therapeutics, Inc. (SRNE) and July 27 Deadline

    author_avatar
    NASDAQ Market News